Locked System (MLS) Therapy Laser was developed in an effort to produce an efficient and simultaneous effect on pain, inflammation, and edema, exceeding the limits of traditional LLLT (low power) and concerns of HP (high power) laser therapy. MLS technology delivers therapeutic wavelengths, 808nm (anti-edemic and anti-inflammatory) and 905nm (analgesic), allowing a tissue penetration depth of 3-4 cm. An energetic synergy is created when delivering these wavelengths that produces greater anti-inflammatory and analgesic effects than either can produce on its own, while minimizing the risk of thermal damage. It is this unique combination and synchronization of continuous and pulsed emissions that characterizes MLS and distinguishes it from other Class IV lasers.
Unlike early-generation Class IV technology, MLS Laser Therapy has the capability to deliver controlled laser energy. This unique feature provides more accurate therapeutic dose delivery, which means consistent and repeatable results.
MLS Laser Therapy is quickly becoming the standard of care in alleviating both acute and chronic pain. This patented, FDA-cleared technology has an 85% – 90% efficacy rate in relieving pain and inflammation, eliminates risk from surgery and prescription pain killers, has no negative side effects, and restores patients’ lives.